In addition, in experimental studies, the combination of 1D11 mAb with IL-2 has allowed the administration of lower non-toxic doses of IL-2, while still maintaining strong anti-tumor responses mediated by both NK and CD8 T cells on tumor mouse models [128]. This evidence concerns the gene CD8A and neoplasm.